A PHASE II PROSPECTIVE STUDY OF HIGH-DOSE myeloablative therapy, WITH STEM CELL DEVICES SUPPORT IN ELDERLY PATIENTS (from 65 to 76 years) with relapsed aggressive non-Hodgkin lymphoma OR RESISTANT TO first line THERAPY.
Phase of Trial: Phase II
Latest Information Update: 20 Feb 2018
At a glance
- Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Cytarabine (Primary) ; Dexamethasone (Primary) ; Etoposide (Primary) ; Ifosfamide (Primary) ; Rituximab (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 20 Feb 2018 New trial record